Home › Research › Mild cognitive impairment
Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease
Huiping Guo, Xiaoming Shen, Mengke Lyu, Guangsheng Zhou, Chongchong Chen, Baofu Xing, Yan‐Ming Xie. Frontiers in Neurology, 2025-08-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Parkinson's disease (PD), as a common neurodegenerative disorder, its associated mild cognitive impairment (PD-mild cognitive impairment, PD-MCI) is a key prodromal stage in the progression to PD-dementia (PDD). Cognitive dysfunction seriously affects the quality of life of patients. Early diagnosis of PD-MCI is crucial for the prognosis of the disease. At present, traditional clinical diagnosis mainly relies on neuropsychological tests, but it has limitations such as low sensitivity and being easily interfered by subjective factors. It is difficult to achieve early and accurate identification of PD-MCI, which greatly affects the intervention timing and prognosis of the disease. This article summarizes the research progress of multimodal biomarkers in the early diagnosis of PD-MCI, mainly including the comprehensive application of neuroimaging biomarkers, humoral biomarkers, genetic and molecular biomarkers, digital biomarkers, and clinical assessment, providing new theoretical basis and technical paths for promoting the early diagnosis of PD-MCI. It is of great clinical significance and social value to assist in the formulation of individualized intervention strategies, delay the progression of diseases to dementia, improve the quality of life of patients, and reduce the medical burden on families and society.
What this study adds
Evidence grade: Low
This review summarizes multimodal biomarkers for early diagnosis of mild cognitive impairment in Parkinson's disease. It is about diagnosis only and does not test any treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Guo, H., Shen, X., Lyu, M., Zhou, G., Chen, C., Xing, B., et al. (2025). Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease. Frontiers in Neurology. https://doi.org/10.3389/fneur.2025.1652378
Vancouver
Guo H, Shen X, Lyu M, Zhou G, Chen C, Xing B, et al. Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease. Frontiers in Neurology. 2025. doi:10.3389/fneur.2025.1652378. PMID: 40948659.
BibTeX
@article{guo2025-40948659,
author = {Guo, Huiping and Shen, Xiaoming and Lyu, Mengke and Zhou, Guangsheng and Chen, Chongchong and Xing, Baofu and Xie, Yan‐Ming},
title = {{Research progress of multimodal biomarkers in the early diagnosis of mild cognitive impairment in Parkinson’s disease}},
journal = {Frontiers in Neurology},
year = {2025},
doi = {10.3389/fneur.2025.1652378},
pmid = {40948659},
url = {https://doi.org/10.3389/fneur.2025.1652378}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Early diagnosis of PD-MCI is crucial for the prognosis of the disease.
- At present, traditional clinical diagnosis mainly relies on neuropsychological tests, but it has limitations such as low sensitivity and being easily interfered by subjective factors.
- It is difficult to achieve early and accurate identification of PD-MCI, which greatly affects the intervention timing and prognosis of the disease.
- This article summarizes the research progress of multimodal biomarkers in the early diagnosis of PD-MCI, mainly including the comprehensive application of neuroimaging biomarkers, humoral biomarkers, genetic and molecular biomarkers, digital biomarkers, and clinical assessment, providing new theoretical basis and technical paths for promoting the early diagnosis of PD-MCI.
- It is of great clinical significance and social value to assist in the formulation of individualized intervention strategies, delay the progression of diseases to dementia, improve the quality of life of patients, and reduce the medical burden on families and society.
Why it matters
This review summarizes multimodal biomarkers for early diagnosis of mild cognitive impairment in Parkinson's disease. It is about diagnosis only and does not test any treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in Neurology) |
| Journal's citation record | 2 / 4 | Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Yan‐Ming Xie: h-index 22 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | China Academy of Chinese Medical Sciences: institution h-index 304 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40948659) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fneur.2025.1652378
- PubMed: 40948659
- Original source →
- Free full text: Frontiers in Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Mild cognitive impairment from nearby years
Also tagged “mini-mental”
840 studies in the library carry the topic tag “mini-mental”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.